ccRCC has stood out collectively of the foremost immune-infiltrated tumors, and clinically anti-PD-1/PD-L1 antibody has been permitted within the front-line setting of advanced or metastatic ccRCC (Motzer et al., 2015). This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.